Knight Therapeutics (GUD) News Today C$5.26 +0.05 (+0.96%) (As of 11:15 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Raymond James Has Lowered Expectations for Knight Therapeutics (TSE:GUD) Stock PriceNovember 18 at 1:40 AM | americanbankingnews.comQ4 Earnings Forecast for TSE:GUD Issued By Raymond JamesNovember 17, 2024 | americanbankingnews.comSime Armoyan Purchases 90,300 Shares of Knight Therapeutics Inc. (TSE:GUD) StockNovember 16, 2024 | insidertrades.comKnight Therapeutics (TSE:GUD) Upgraded at Raymond JamesRaymond James raised shares of Knight Therapeutics to a "moderate buy" rating in a research report on Friday.November 16, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Buys 90,300 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan acquired 90,300 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of C$5.13 per share, for a total transaction of C$463,672.44.November 15, 2024 | marketbeat.comQ4 Earnings Estimate for TSE:GUD Issued By Raymond JamesKnight Therapeutics Inc. (TSE:GUD - Free Report) - Research analysts at Raymond James issued their Q4 2024 EPS estimates for shares of Knight Therapeutics in a research report issued on Wednesday, November 13th. Raymond James analyst R. Sarugaser expects that the company will post earnings per shNovember 15, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Buys 20,000 SharesNovember 12, 2024 | insidertrades.comStifel Canada Issues Negative Forecast for TSE:GUD EarningsNovember 12, 2024 | americanbankingnews.comStifel Canada Issues Negative Outlook for TSE:GUD EarningsKnight Therapeutics Inc. (TSE:GUD - Free Report) - Equities researchers at Stifel Canada reduced their Q4 2024 EPS estimates for Knight Therapeutics in a research report issued on Thursday, November 7th. Stifel Canada analyst J. Keywood now expects that the company will post earnings of $0.06 perNovember 11, 2024 | marketbeat.comKnight Therapeutics (GUD) Set to Announce Earnings on ThursdayKnight Therapeutics (TSE:GUD) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Trading Down 0.3% - Time to Sell?Knight Therapeutics (TSE:GUD) Stock Price Down 0.3% - Here's WhyOctober 15, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 300,000 SharesSeptember 22, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sells C$1,839,000.00 in StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 300,000 shares of the business's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00.September 21, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Sets New 52-Week High at $6.23Knight Therapeutics (TSE:GUD) Hits New 1-Year High at $6.23September 17, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Stock Price Up 7.3%Knight Therapeutics (TSE:GUD) Stock Price Up 7.3%September 11, 2024 | marketbeat.comAmal Khouri Sells 5,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockAugust 21, 2024 | insidertrades.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Senior Officer Sells 5,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 5,000 shares of the company's stock in a transaction on Monday, August 19th. The stock was sold at an average price of C$5.78, for a total value of C$28,919.00.August 19, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Knight Therapeutics Inc.'s FY2024 Earnings (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Stifel Canada cut their FY2024 EPS estimates for shares of Knight Therapeutics in a report released on Monday, August 12th. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings per share of $0.06 for the year, downAugust 15, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Upgraded at Stifel CanadaStifel Canada raised shares of Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday.August 14, 2024 | marketbeat.comStifel Canada Weighs in on Knight Therapeutics Inc.'s Q3 2024 Earnings (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Analysts at Stifel Canada decreased their Q3 2024 earnings per share (EPS) estimates for shares of Knight Therapeutics in a research report issued on Monday, August 12th. Stifel Canada analyst J. Keywood now forecasts that the company will earn $August 14, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Rating Increased to Buy at Stifel NicolausStifel Nicolaus upgraded Knight Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from C$5.75 to C$6.75 in a research note on Tuesday.August 13, 2024 | marketbeat.comKnight Therapeutics Inc. (GUD.TO)August 12, 2024 | ca.finance.yahoo.comFY2025 EPS Estimates for Knight Therapeutics Inc. Lifted by Raymond James (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Investment analysts at Raymond James raised their FY2025 earnings per share estimates for Knight Therapeutics in a report released on Thursday, August 8th. Raymond James analyst R. Sarugaser now expects that the company will post earnings of $0.0August 12, 2024 | marketbeat.comKnight Therapeutics earnings: here's what to expectAugust 8, 2024 | markets.businessinsider.comKnight Therapeutics Inc. (KHTRF)July 24, 2024 | finance.yahoo.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Senior Officer Sells 10,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of C$5.70, for a total value of C$57,000.00.July 11, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 10,000 SharesJuly 4, 2024 | insidertrades.comAmal Khouri Sells 20,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockJune 15, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 20,000 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 20,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total transaction of C$116,022.00.June 13, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Director Buys C$29,000.00 in StockJune 6, 2024 | insidertrades.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Director Buys 5,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Director Jonathan Ross Goodman bought 5,000 shares of the stock in a transaction dated Wednesday, June 5th. The stock was bought at an average cost of C$5.80 per share, for a total transaction of C$29,000.00.June 5, 2024 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Director Sells 15,000 Shares of StockMay 30, 2024 | insidertrades.comGUD:CA Knight Therapeutics Inc.May 15, 2024 | seekingalpha.comKnight Therapeutics (TSE:GUD) Reaches New 52-Week High at $6.17Knight Therapeutics (TSE:GUD) Reaches New 12-Month High at $6.17May 14, 2024 | marketbeat.comKnight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call TranscriptMay 12, 2024 | seekingalpha.comStifel Nicolaus Increases Knight Therapeutics (TSE:GUD) Price Target to C$5.75Stifel Nicolaus lifted their price objective on shares of Knight Therapeutics from C$5.40 to C$5.75 in a research report on Friday.May 10, 2024 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 15,000 Shares of StockMay 9, 2024 | insidertrades.comKnight Therapeutics (TSE:GUD) Reaches New 12-Month High at $5.95Knight Therapeutics (TSE:GUD) Reaches New 12-Month High at $5.95May 6, 2024 | marketbeat.comKnight Therapeutics (GUD) to Release Quarterly Earnings on ThursdayKnight Therapeutics (TSE:GUD) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 3, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) PT Raised to C$5.40Stifel Nicolaus lifted their price target on shares of Knight Therapeutics from C$5.25 to C$5.40 and gave the company a "hold" rating in a research report on Wednesday.May 1, 2024 | marketbeat.comKnight Therapeutics Inc (GUD)April 21, 2024 | investing.comTSX Healthcare in April 2024: The Best Stocks to Buy Right NowApril 16, 2024 | msn.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 10,900 SharesApril 16, 2024 | insidertrades.comSime Armoyan Sells 10,900 Shares of Knight Therapeutics Inc. (TSE:GUD) StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 10,900 shares of Knight Therapeutics stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of C$5.95, for a total transaction of C$64,855.00.April 15, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Reaches New 1-Year High at $5.80Knight Therapeutics (TSE:GUD) Hits New 1-Year High at $5.80April 10, 2024 | marketbeat.comKnight to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | finance.yahoo.comKnight Therapeutics Inc. (TSE:GUD) Insider Buys C$32,550.00 in StockApril 9, 2024 | insidertrades.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Purchases 6,200 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan bought 6,200 shares of the company's stock in a transaction on Monday, April 1st. The shares were acquired at an average price of C$5.25 per share, with a total value of C$32,550.00.April 8, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Acquires 351,000 SharesMarch 26, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Buys 351,000 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan bought 351,000 shares of the company's stock in a transaction dated Monday, March 25th. The stock was acquired at an average price of C$5.25 per share, for a total transaction of C$1,842,750.00.March 25, 2024 | marketbeat.com Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in… >> YES! Send Me My FREE Gold Guide! GUD Media Mentions By Week GUD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GUD News Sentiment▼0.880.47▲Average Medical News Sentiment GUD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GUD Articles This Week▼121▲GUD Articles Average Week Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TLRY News CRON News WEED News CPH News ACB News OGI News CRDL News RX News HLS News MDP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:GUD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
